Policy & Regulation
WuXi XDC's Singapore site BCM3 facility achieves GMP release
18 August 2026 - WuXi XDC Cayman Inc. (HKG: 2268), a China-based global Contract Research, Development and Manufacturing Organisation (CRDMO) involved in the bioconjugate industry, announced on Tuesda...
Slingshot Bio introduces ViaComp Ultra Amine
18 August 2026 - Slingshot Bio, Inc., a California-based company involved in precision cell mimic controls for flow cytometry, announced on Monday the commercial launch of ViaComp Ultra Amine, a next-...
Leal Therapeutics announces USD30m Series A extension and initiates Phase 1b/2a clinical trial of LTX-001 in schizophrenia
18 August 2026 - Leal Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company developing neuro-metabolic therapeutics, announced on Monday a second close of USD30m of its Series A fina...
Can-Fite reports preclinical data supporting Phase IIb pancreatic cancer study
17 August 2026 - Israel-based clinical-stage biotechnology company Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), which develops small-molecule drugs for oncological and inflammatory disea...
Acurx receives FDA conditional acceptance for ibezapolstat brand name
17 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) disclosed on Monday that it has received conditional FDA acceptance for CIFBEZY, the proposed proprietary name for i...
AstraZeneca reports positive Phase III results for Tagrisso and Orpathys
17 August 2026 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday announced positive high-level results from the SAFFRON Phase III trial, showing Tagrisso (osimertinib...